COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study

Abstract

Background Early reports on patients with cancer and COVID-19 have suggested a high mortality rate compared with the general population. Patients with thoracic malignancies are thought to be particularly susceptible to COVID-19 given their older age, smoking habits, and pre-existing cardiopulmonary comorbidities, in addition to cancer treatments. We aimed to study the effect of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on patients with thoracic malignancies. MethodsThe Thoracic Cancers International COVID-19 Collaboration (TERAVOLT) registry is a multicentre observational study composed of a cross-sectional component and a longitudinal cohort component. Eligibility criteria were the presence of any thoracic cancer (non-small-cell lung cancer [NSCLC], small-cell lung cancer, mesothelioma, thymic epithelial tumours, and other pulmonary neuroendocrine neoplasms) and a COVID-19 diagnosis, either laboratory confirmed with RT-PCR, suspected with symptoms and contacts, or radiologically suspected cases with lung imaging features consistent with COVID-19 pneumonia and symptoms. Patients of any age, sex, histology, or stage were considered eligible, including those in active treatment and clinical follow-up. Clinical data were extracted from medical records of consecutive patients from Jan 1, 2020, and will be collected until the end of pandemic declared by WHO. Data on demographics, oncological history and comorbidities, COVID-19 diagnosis, and course of illness and clinical outcomes were collected. Associations between demographic or clinical characteristics and outcomes were measured with odds ratios (ORs) with 95% CIs using univariable and multivariable logistic regression, with sex, age, smoking status, hypertension, and chronic obstructive pulmonary disease included in multivariable analysis. This is a preliminary analysis of the first 200 patients. The registry continues to accept new sites and patient data. Findings Between March 26 and April 12, 2020, 200 patients with COVID-19 and thoracic cancers from eight countries were identified and included in the TERAVOLT registry; median age was 68•0 years (61•8-75•0) and the majority had an Eastern Cooperative Oncology Group performance status of 0-1 (142 [72%] of 196 patients), were current or former smokers (159 [81%] of 196), had non-small-cell lung cancer (151 [76%] of 200), and were on therapy at the time of COVID-19 diagnosis (147 [74%] of 199), with 112 (57%) of 197 on first-line treatment. 152 (76%) patients were hospitalised and 66 (33%) died. 13 (10%) of 134 patients who met criteria for ICU admission were admitted to ICU; the remaining 121 were hospitalised, but were not admitted to ICU. Univariable analyses revealed that being older than 65 years (OR 1•88, 95% 1•00-3•62), being a current or former smoker (4•24, 1•70-12•95), receiving treatment with chemotherapy alone (2•54, 1•09-6•11), and the presence of any comorbidities (2•65, 1•09-7•46) were associated with increased risk of death. However, in multivariable analysis, only smo...

Impact of COVID-19 on anxiety levels among patients with cancer actively treated with systemic therapy

“…COVID-19 has strikingly high mortality of around 30% in patients with lung cancer so high fear and anxiety could be expected in this group, but our study revealed that patients with lung cancer were affected by anxiety the least. 33 Also, patients with genitourinary cancers had a low fear of COVID-19. It is important to underline that majority of patients with lung or urogenital cancers were male individuals, who according to the multivariate model have significantly lower anxiety levels.…”

COVID-19 risk for patients undergoing anticancer treatment at the outpatient clinic of the National Cancer Institute of Milan: the COVINT study

“…In this light, we do believe that the risk of COVID-19 and its complications is higher in the most fragile patients, especially those with advanced, more aggressive cancers. 9 In addition, only one patient was admitted to ICU, suggesting that a cancer diagnosis represented a criterion to select patients for intensive care. 9 The small number of confirmed COVID-19 cases clearly limit our observation.…”

“… 9 In addition, only one patient was admitted to ICU, suggesting that a cancer diagnosis represented a criterion to select patients for intensive care. 9 The small number of confirmed COVID-19 cases clearly limit our observation. Indeed, while single centre reports represent a relevant source of documentation for the extraordinary events of these months, joint multicentre analyses will be vital to get to a deeper understanding of the impact of COVID-19 on the cancer patient population.…”

Fears and Perception of the Impact of COVID-19 on Patients With Lung Cancer: A Mono-Institutional Survey

“…However, severe cases have occurred in individuals without known risk factors ( 6 ). Two prospective trials have investigated the impact of COVID-19 in cancer patients: CCC19 (all cancers) and TERAVOLT (only thoracic cancers) ( 7 , 8 ). In the CCC19 cohort study, 121 (13%) deaths were recorded out of 928 of patients with cancer (82% solid tumors) and the risk factors for mortality were: older age, male sex, ever smoker, number of comorbidities, performance status of 2 or more, active cancer, and prior administration of azithromycin plus hydroxychloroquine ( 7 ).…”

“…Moreover, prior administration of chemotherapy (alone or in combination with immunotherapy), steroids, and anticoagulant therapy may increase risk of death ( 8 ). Following the initial spread of COVID-19 in Italy, a lockdown was imposed on 23 February, 2020 by the Italian government, covering those regions of Italy mostly hit by the pandemic spread.…”